Objective: To observe the effects of Irbesartan combined with Atorvastatin on early diabetic nephropathy patients' serum Cys C, Hcy, TNF-α, ET and TGF-b1 levels. Methods: A total of 60 early diabetic nephropathy ...Objective: To observe the effects of Irbesartan combined with Atorvastatin on early diabetic nephropathy patients' serum Cys C, Hcy, TNF-α, ET and TGF-b1 levels. Methods: A total of 60 early diabetic nephropathy patients were randomly divided into observation group (30 cases) and control group (30 cases). Observation group: Irbesartan combined with Atorvastatin;control group: patients were treated only by Irbesartan. Recording and comparing the levels of Cys C, Hcy, TNF-α, ET and TGF-b1 before and after treatment. Results: (1) Before treatment, there was no statistically significant difference in the serum FBG, TG, Scr, BUN levels between the two groups. After treatment, compared with the same group before treatment, the serum TG, Scr, BUN levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant;(2) Before treatment, there was no statistically significant difference in the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels between the two groups. After treatment, compared with the same group before treatment, the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant. Conclusion: Irbesartan combined with Atorvastatin for early diabetic nephropathy patients can reduce the levels of serum Cys C, Hcy, TNF-α, ET, TGF-b1 and be beneficial to protect their nephritic function.展开更多
Sixty-eight cases of Non-Insulin Dependent Diabetes Mellitus complicated with Nephropathywere randomly divided into two groups : the treated group, 35 cases treated with alcohol extraction of Flos A-belmoschus manihot...Sixty-eight cases of Non-Insulin Dependent Diabetes Mellitus complicated with Nephropathywere randomly divided into two groups : the treated group, 35 cases treated with alcohol extraction of Flos A-belmoschus manihot, Gliclazide and Captopril Tablets; and the control group, 33 cases treated with Gli-clazide and Captopril Tablets, over a period of 8 weeks. The total effective rate in the treated and controlgroup were 83.87% and 31.03% respectively (P< 0 . 01 ) , urinary micro-albumin were 31 . 7 and 76.3mg/L(P < 0. 05) , proteinuria were 0. 41 and 0 . 77g/24hr ( P < 0. 01 ) , blood 2-microglobulin were 3317. 8 and3473. 1 hg/ml ( P < 0. 05) , urinary 2-microglobulin were 367. 2 and 641 . 5ng/ml ( P < 0. 01 ) , urinary N-acetyl- -glucosaminidase (NAG) were 26. 3 and 66. 7u/L ( P < 0. 01 ) , plasma lipid peroxide (LPO) were6. 13 and 8. 78 nmol/L ( P<0. 05) , and plasma superoxide anion were 8. 36 and 10. 42 kcpm respectively( P< 0. 05) . It was suggested that alcohol extraction of Abelmoschus manihot could eliminate oxygen freeradicals, alleviate renal tubular-interstitial diseases, improve renal function, and reduce proteinuria.展开更多
目的:观察前列地尔注射液联合阿托伐他汀治疗早期糖尿病肾病的效果。方法:62例住院糖尿病肾病患者,随机分为治疗组32例和对照组30例,两组患者均给予糖尿病饮食、控制血糖和降血压等常规治疗,对照组给予前列地尔注射液,治疗组在对照组基...目的:观察前列地尔注射液联合阿托伐他汀治疗早期糖尿病肾病的效果。方法:62例住院糖尿病肾病患者,随机分为治疗组32例和对照组30例,两组患者均给予糖尿病饮食、控制血糖和降血压等常规治疗,对照组给予前列地尔注射液,治疗组在对照组基础上联合阿托伐他汀治疗,两组疗程均为4周,分别观察治疗前后两组尿白蛋白排泄率(urinary albumin excretionrate,UAER)、血肌酐(Scr)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)的变化。结果:治疗后与治疗前比较,对照组UAER显著降低(P<0.05)。治疗组UAER、Scr、LDL-C、TC、TG显著降低(P<0.05)。两组治疗后比较,治疗组UAER、Scr、LDL-C、TC、TG显著低于对照组(P<0.05),治疗组疗效优于对照组。结论:前列地尔注射液联合阿托伐他汀治疗早期糖尿病肾病安全更有效。展开更多
基金The Xinjiang Uygur Autonomous Region Natural Science Foundation(number:2015172B022).
文摘Objective: To observe the effects of Irbesartan combined with Atorvastatin on early diabetic nephropathy patients' serum Cys C, Hcy, TNF-α, ET and TGF-b1 levels. Methods: A total of 60 early diabetic nephropathy patients were randomly divided into observation group (30 cases) and control group (30 cases). Observation group: Irbesartan combined with Atorvastatin;control group: patients were treated only by Irbesartan. Recording and comparing the levels of Cys C, Hcy, TNF-α, ET and TGF-b1 before and after treatment. Results: (1) Before treatment, there was no statistically significant difference in the serum FBG, TG, Scr, BUN levels between the two groups. After treatment, compared with the same group before treatment, the serum TG, Scr, BUN levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant;(2) Before treatment, there was no statistically significant difference in the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels between the two groups. After treatment, compared with the same group before treatment, the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant. Conclusion: Irbesartan combined with Atorvastatin for early diabetic nephropathy patients can reduce the levels of serum Cys C, Hcy, TNF-α, ET, TGF-b1 and be beneficial to protect their nephritic function.
文摘Sixty-eight cases of Non-Insulin Dependent Diabetes Mellitus complicated with Nephropathywere randomly divided into two groups : the treated group, 35 cases treated with alcohol extraction of Flos A-belmoschus manihot, Gliclazide and Captopril Tablets; and the control group, 33 cases treated with Gli-clazide and Captopril Tablets, over a period of 8 weeks. The total effective rate in the treated and controlgroup were 83.87% and 31.03% respectively (P< 0 . 01 ) , urinary micro-albumin were 31 . 7 and 76.3mg/L(P < 0. 05) , proteinuria were 0. 41 and 0 . 77g/24hr ( P < 0. 01 ) , blood 2-microglobulin were 3317. 8 and3473. 1 hg/ml ( P < 0. 05) , urinary 2-microglobulin were 367. 2 and 641 . 5ng/ml ( P < 0. 01 ) , urinary N-acetyl- -glucosaminidase (NAG) were 26. 3 and 66. 7u/L ( P < 0. 01 ) , plasma lipid peroxide (LPO) were6. 13 and 8. 78 nmol/L ( P<0. 05) , and plasma superoxide anion were 8. 36 and 10. 42 kcpm respectively( P< 0. 05) . It was suggested that alcohol extraction of Abelmoschus manihot could eliminate oxygen freeradicals, alleviate renal tubular-interstitial diseases, improve renal function, and reduce proteinuria.
文摘目的:观察前列地尔注射液联合阿托伐他汀治疗早期糖尿病肾病的效果。方法:62例住院糖尿病肾病患者,随机分为治疗组32例和对照组30例,两组患者均给予糖尿病饮食、控制血糖和降血压等常规治疗,对照组给予前列地尔注射液,治疗组在对照组基础上联合阿托伐他汀治疗,两组疗程均为4周,分别观察治疗前后两组尿白蛋白排泄率(urinary albumin excretionrate,UAER)、血肌酐(Scr)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)的变化。结果:治疗后与治疗前比较,对照组UAER显著降低(P<0.05)。治疗组UAER、Scr、LDL-C、TC、TG显著降低(P<0.05)。两组治疗后比较,治疗组UAER、Scr、LDL-C、TC、TG显著低于对照组(P<0.05),治疗组疗效优于对照组。结论:前列地尔注射液联合阿托伐他汀治疗早期糖尿病肾病安全更有效。
